Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Neutral
Key Numbers
Market Cap
$170B
P/E
70
Revenue Growth
+17.0%
Gross Margin
N/A
ROE
N/A
About Intuitive Surgical
As a large-cap healthcare company trading on the NASDAQ, Intuitive Surgical has established itself, with indirect exposure to artificial intelligence and robotics through its adjacent operations. Robotic surgery pioneer using AI for surgical planning and autonomy. Valued at 70x trailing earnings with a $170B market capitalization, the company demonstrates consistent top-line gains at +17% year-over-year.
Expert Coverage
Unlock Full ISRG Analysis
Expert analysis and coverage for Intuitive Surgical
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-10-06
More in AI & Robotics
META
Meta Platforms
89
True North
Mixed
Social media giant pivoting to AI-first strategy with Llama open-source models.
NASDAQ
MCap $1.5TRev +22%P/E 28MSFT
Microsoft Corporation
87
True North
Mixed
Cloud and AI platform leader with Azure, Copilot, and OpenAI partnership.
NASDAQ
MCap $3.1TRev +16%P/E 36SMCI
Super Micro Computer
87
True North
Pure Play
AI server and rack solutions optimized for GPU-intensive workloads.
NASDAQ
MCap $25BRev +110%P/E 18CRM
Salesforce Inc.
87
True North
Mixed
Enterprise CRM leader with Einstein AI agents transforming customer relationship management.
NYSE
MCap $280BRev +11%P/E 45More in Biotech & Genomics
LLY
Eli Lilly and Company
92
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65DXCM
DexCom Inc.
90
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55RXRX
Recursion Pharmaceuticals
90
True North
Pure Play
AI-driven drug discovery platform using machine learning to decode biology at scale.
NASDAQ
MCap $4BRev +55%ALNY
Alnylam Pharmaceuticals
88
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%